Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00815880 · ClinicalTrials.gov registry record · NA
C-Pulse IDE Feasibility Study- A Heart Assist System
A NA study, sponsored by Nuwellis.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT00815880: Completed NA study, sponsored by Nuwellis.
NCT00815880 is a NA study that has completed, run by Nuwellis. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00815880, a NA study, has completed, sponsored by Nuwellis.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The C-Pulse Feasibility Study is evaluating the safety and performance of a new product for the treatment of heart failure. The product is designed to help reduce the symptoms of heart failure and help patients function better with daily activities. The study evaluates multiple measures of heart function and whether the patient's quality of life has been improved since the device implant. The patient will have several visits after the device implant to assess how well they are doing and to monitor any safety concerns.
Primary Outcome
Amount of participants that did not exit study for reasons including worsening heart failure resulting in hospitalization, LVAD implantation, study withdrawal or death.
Interventions
- DEVICE C-Pulse™ (Implantable Counterpulsation Therapy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-09-10 |
| Est. Completion | 2018-09-07 |
| Phase | NA |
What the finished NCT00815880 record still lists
NCT00815880 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which C-Pulse™ (Implantable Counterpulsation Therapy) is the first listed.
NCT00815880 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00815880 about?
NCT00815880 is a clinical study titled "C-Pulse IDE Feasibility Study- A Heart Assist System". The C-Pulse Feasibility Study is evaluating the safety and performance of a new product for the treatment of heart failure. The product is designed to help reduce the symptoms of heart failure and help patients function better with daily activities. The study evaluates multiple measures of heart fun...
What is the current status of trial NCT00815880?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2008-09-10. Estimated completion is 2018-09-07.
What interventions are being tested in trial NCT00815880?
The interventions under investigation include: C-Pulse™ (Implantable Counterpulsation Therapy) (DEVICE).
Who is sponsoring clinical trial NCT00815880?
This trial is sponsored by Nuwellis, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00815880's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI